跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NADPH
首页
药物
NADPH
Experimental
Small Molecule
NADPH
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
技术标识符
化学式
C
21
H
30
N
7
O
17
P
3
CAS 编号
53-57-6
UNII ID
381Q4X082D
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Cytochrome P450 monooxygenase CYP52A2B from Candida tropicalis
US 7049112 B2
申请人: COGNIS CORP
优先权: 2001
US
11 件公开
Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP 2166010 A1
申请人: GENKYO TEX SA
优先权: 2008
CN
EP
US
9 件公开
EP 2002835 A1
申请人: GENKYO TEX
优先权: 2007
CN
EP
US
6 件公开
US 8455485 B2
申请人: PAGE PATRICK
优先权: 2008
CN
EP
US
6 件公开
US 8455486 B2
申请人: PAGE PATRICK
优先权: 2008
EP
US
5 件公开
US 8481562 B2
申请人: PAGE PATRICK
优先权: 2008
EP
US
5 件公开
Means and methods of using a NADPH oxidase inhibitor for the treatment of hearing loss and phantom hearing
US 8088359 B2
申请人: KRAUSE KARL-HEINZ
优先权: 2004
EP
US
7 件公开
Compounds as NADPH oxidase inhibitors
US 12202816 B2
申请人: CALLIDITAS THERAPEUTICS SUISSE SA
优先权: 2018
CN
EP
US
WO
6 件公开
NADPH OXIDASE INHIBITORS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND APPLICATION THEREOF
EP 3810143 B1
申请人: TAIWANJ PHARMACEUTICALS CO LTD
优先权: 2018
CN
EP
US
WO
5 件公开
NOVEL THIOHYDANTOIN DERIVATIVES AND USES THEREOF
EP 4205740 C0
申请人: CELROS BIOTECH
优先权: 2020
CN
EP
US
WO
5 件公开
AN ISOLATED PHYCOBILIN FOR USE IN A METHOD FOR PROPHYLAXIS OR TREATMENT OF A MEDICAL CONDITION
EP 3597188 A1
申请人: PCB ASS INC
优先权: 2006
CN
EP
US
5 件公开
SYNERGISTIC ACTIVITY OF MODULATORS OF THE NO METABOLISM AND OF NADPH OXIDASE IN THE SENSITIZATION OF TUMOR CELLS
US 2013171104 A1
申请人: BAUER GEORG
优先权: 2010
EP
US
WO
5 件公开
HYALURONIC ACID NANOPARTICLES COMPRISING NADPH OXIDASES INHIBITORS AND USES IN TREATING CANCER
EP 3946297 A4
申请人: UNIV EMORY
优先权: 2019
EP
US
WO
5 件公开
Autoimmune conditions and NADPH oxidase defects
US 7294652 B2
申请人: AREXIS AB
优先权: 2003
US
5 件公开
CN 101404985 A
申请人: BIOVITRUM AB PUBL
优先权: 2006
CN
US 2008051451 A1
申请人: LINSCHOTEN MARCEL
优先权: 2007
US
第 1 / 10 页
上一页
下一页
药物
反馈